Sorafenib VS TACE in HCC Patients With Portal Vein Invasion
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The investigators are going to compare the therapeutic effect of sorafenib and transarterial
chemoembolization in advanced hepatocellular carcinoma with major branch of portal vein
invasion.